You are here: Industry Insights > Selinexor

News List

FDA Approves Selinexor for Relapsed/Refractory Diffuse Large B-Cell Lymphoma americanpharmaceuticalreview
July 03, 2020
The Food and Drug Administration (FDA) granted accelerated approval to selinexor (XPOVIO, Karyopharm Therapeutics) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ...
Novel Therapy Treats Triple-Class Refractory Multiple Myeloma drugs
August 26, 2019
The combination of selinexor and dexamethasone seems effective in treating patients with multiple myeloma that has not responded to standard therapies...
Selinexor Offers Hope Against a Tough-to-Treat Blood Cancer drugs
August 22, 2019
Patients with a form of blood cancer known as multiple myeloma who haven't responded to other therapies might have a new weapon against the disease, researchers say.
FDA Grants Accelerated Approval to Selinexor americanpharmaceuticalreview
July 08, 2019
The Food and Drug Administration (FDA) has granted accelerated approval to selinexor (XPOVIO, Karyopharm Therapeutics) in combination with dexamethasone for adult patients with ...
FDA Approves Xpovio (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma drugs
July 04, 2019
FDA Approves Xpovio (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
Karyopharm slumps, then leaps on selinexor multiple myeloma data fiercebiotech
May 02, 2018
Karyopharm Therapeutics’ stock took a bit of a roller-coaster ride Monday—it dipped 15% as investors waited for an update on the phase ...

Previous page 1 2 Next page